Balchem Co. (NASDAQ:BCPC) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Balchem Co. (NASDAQ:BCPC - Free Report) by 6.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 83,651 shares of the basic materials company's stock after purchasing an additional 4,812 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.26% of Balchem worth $14,723,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of BCPC. nVerses Capital LLC acquired a new position in shares of Balchem in the 3rd quarter valued at $35,000. Blue Trust Inc. lifted its position in Balchem by 642.5% in the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company's stock valued at $148,000 after buying an additional 726 shares during the last quarter. GAMMA Investing LLC lifted its position in Balchem by 73.4% in the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company's stock valued at $148,000 after buying an additional 356 shares during the last quarter. Private Advisor Group LLC purchased a new position in Balchem during the third quarter worth about $220,000. Finally, TD Asset Management Inc acquired a new stake in shares of Balchem during the second quarter valued at about $200,000. Hedge funds and other institutional investors own 87.91% of the company's stock.

Balchem Stock Up 0.7 %

BCPC stock traded up $1.15 during mid-day trading on Friday, reaching $177.53. The company had a trading volume of 64,233 shares, compared to its average volume of 121,493. The firm has a fifty day simple moving average of $174.80 and a 200 day simple moving average of $168.32. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98. The company has a market capitalization of $5.77 billion, a price-to-earnings ratio of 47.72, a price-to-earnings-growth ratio of 5.36 and a beta of 0.67. Balchem Co. has a fifty-two week low of $131.10 and a fifty-two week high of $186.03.

Wall Street Analyst Weigh In

BCPC has been the subject of a number of research analyst reports. StockNews.com upgraded Balchem from a "hold" rating to a "buy" rating in a report on Monday, October 28th. HC Wainwright raised their price objective on shares of Balchem from $185.00 to $190.00 and gave the company a "buy" rating in a research note on Monday, November 4th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.